Does an Alternative Sunitinib Dosing Schedule Really Improve Survival Outcomes Over a Conventional Dosing Schedule in Patients with Metastatic Renal Cell Carcinoma? An Updated Systematic Review and Meta-Analysis

Treatment-related adverse events (AEs) can obfuscate the maintenance of a conventional schedule of sunitinib in patients with metastatic renal cell carcinoma. Accordingly, alternative schedules seeking to improve the safety profile of sunitinib have been tested. Recently, two meta-analyses similarly...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Doo Yong, Kang, Dong Hyuk, Kim, Jong Won, Kim, Do Kyung, Lee, Joo Yong, Hong, Chang Hee, Cho, Kang Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966535/
https://www.ncbi.nlm.nih.gov/pubmed/31766332
http://dx.doi.org/10.3390/cancers11121830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966535/
https://www.ncbi.nlm.nih.gov/pubmed/31766332
http://dx.doi.org/10.3390/cancers11121830

Ejemplares similares